GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Corix Bioscience Inc (GREY:CXBS) » Definitions » Cash Conversion Cycle

Corix Bioscience (Corix Bioscience) Cash Conversion Cycle : 0.00 (As of Sep. 2017)


View and export this data going back to 2008. Start your Free Trial

What is Corix Bioscience Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Corix Bioscience's Days Sales Outstanding for the three months ended in Sep. 2017 was 0.
Corix Bioscience's Days Inventory for the three months ended in Sep. 2017 was .
Corix Bioscience's Days Payable for the three months ended in Sep. 2017 was .
Therefore, Corix Bioscience's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2017 was 0.00.


Corix Bioscience Cash Conversion Cycle Historical Data

The historical data trend for Corix Bioscience's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corix Bioscience Cash Conversion Cycle Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
Cash Conversion Cycle
Get a 7-Day Free Trial - - - - 1.05

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Corix Bioscience's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corix Bioscience's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's Cash Conversion Cycle falls into.



Corix Bioscience Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Corix Bioscience's Cash Conversion Cycle for the fiscal year that ended in Dec. 2016 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=1.05+-
=1.05

Corix Bioscience's Cash Conversion Cycle for the quarter that ended in Sep. 2017 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corix Bioscience  (GREY:CXBS) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Corix Bioscience Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Corix Bioscience's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Corix Bioscience (Corix Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

Corix Bioscience (Corix Bioscience) Headlines

No Headlines